Literature DB >> 16616056

Endothelial nitric oxide synthase G894T gene polymorphism in Chilean subjects with coronary artery disease and controls.

Priscilla C Jaramillo1, Alvaro Muñoz M, Cecilia Lanas M, Fernando Lanas Z, Luis A Salazar.   

Abstract

BACKGROUND: Nitric oxide (NO) from the endothelium, produced by oxidation of l-arginine to L-citruline for the action at the endothelial nitric oxide synthase (eNOS), is considered an important atheroprotective factor. The Glu298Asp (G894T) polymorphic variant of the eNOS gene has been implicated in the development of coronary artery disease (CAD). We investigated the association between occurrence of CAD documented by angiography and the G894T polymorphism of the NOS3 gene in Chilean individuals.
METHODS: A total of 112 unrelated patients with diagnosis of CAD and 72 controls were included in this study. G894T gene polymorphism was analyzed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP).
RESULTS: The frequency of TT homozygous genotype for G894T polymorphism was 7% in CAD patients and 1% in the control group. However, the genotype distribution and allele frequencies were not significantly different between CAD and control subjects (P>0.05). Moreover, the odds ratio for CAD associated with the T variant failed to reach statistical significance (OR=1.5; 95% CI: 0.87-2.59, P>0.05).
CONCLUSION: These findings suggest that the G894T polymorphism of the eNOS gene was not associated with CAD in Chilean individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616056     DOI: 10.1016/j.cca.2006.02.030

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  Lack of association between Glu298Asp polymorphism and coronary artery disease in North Indians.

Authors:  Himanshu Rai; Jacqui Fitt; A K Sharma; Nakul Sinha; Sudeep Kumar; C M Pandey; Suraksha Agrawal; Sarabjit Mastana
Journal:  Mol Biol Rep       Date:  2011-12-30       Impact factor: 2.316

2.  MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy.

Authors:  Kathleen Saavedra; Karla Leal; Nicolás Saavedra; Yalena Prado; Isis Paez; Carmen G Ubilla; Gabriel Rojas; Luis A Salazar
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

Review 3.  Association of endothelial nitric oxide synthase gene polymorphisms with coronary artery disease: an updated meta-analysis and systematic review.

Authors:  Himanshu Rai; Farah Parveen; Sudeep Kumar; Aditya Kapoor; Nakul Sinha
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

4.  Endothelial nitric oxide synthase gene Glu298Asp polymorphism in patients with coronary artery disease.

Authors:  Saeedeh Salimi; Mohsen Firoozrai; Hamid Zand; Alireza Nakhaee; Sayed M Shafiee; Heidar Tavilani; Ahmad Mohebbi
Journal:  Ann Saudi Med       Date:  2010 Jan-Feb       Impact factor: 1.526

5.  SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.

Authors:  Yalena Prado; Nicolás Saavedra; Tomás Zambrano; Jenny Lagos; Alexy Rosales; Luis A Salazar
Journal:  Int J Mol Sci       Date:  2015-08-31       Impact factor: 5.923

6.  Meta-Analysis of NOS3 G894T Polymorphisms with Air Pollution on the Risk of Ischemic Heart Disease Worldwide.

Authors:  Robin Johns; Zhao-Feng Chen; Lufei Young; Flordelis Delacruz; Nien-Tzu Chang; Chong Ho Yu; S Pamela K Shiao
Journal:  Toxics       Date:  2018-08-01

7.  Atorvastatin Increases the Expression of Long Non-Coding RNAs ARSR and CHROME in Hypercholesterolemic Patients: A Pilot Study.

Authors:  Isis Paez; Yalena Prado; Carmen G Ubilla; Tomás Zambrano; Luis A Salazar
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.